Biopsy Devices: Technology and Global Markets

Report Highlights

The global market for biopsy devices should reach around roughly $2.1 billion by 2020 from over $1.5 billion in 2015, a compound annual growth rate (CAGR) of 6.2% from 2015 to 2020.

Report Includes

• An overview of the global biopsy devices market.
• Analyses of global market trends, with data from 2014, estimates for 2015, and projections of compound annual growth rates (CAGRs) through 2020
• Segmented analyses based on devices, therapeutic segments, and geographies
• Information on key devices such as breast biopsy devices, CNB (core needle biopsy) devices, fine needles, gastro intestinal (GI) biopsy devices, robotic guidance systems technologies involved in thermal ablation techniques and non–thermal ablation techniques
• Analyses of key strategies, competitive insights, and developments of key companies in the market
• Information on both the challenges that must be addressed and opportunities that can be leveraged by market participants
• Evaluation of key and relevant patents
• Analysis of the key strategies, competitive insights and development of key companies in the market

Report Scope

This research report presents an in-depth analysis of the global market for biopsy devices by device type, therapeutic segments and geographic markets. It discusses key devices such as breast biopsy devices, core needle biopsy (CNB) devices, fine needles, gastrointestinal (GI) biopsy devices, robotic guidance systems technologies involved in thermal ablation techniques and nonthermal ablation techniques. The market by type of procedure is also discussed, which includes trends and market estimates of key therapeutic areas such as breast cancer, gastrointestinal cancer, lung cancer and cervical cancer, among others. The report focuses on key imaging technologies used in the process of performing biopsies such as ultrasound, magnetic resonance imaging (MRI), computed tomography (CT) and others. The report also reviews the supply chain from manufacturers to surgeons.

The report excludes drugs used during a biopsy and any device that is used in the cancer treatment process.

Analyst Credentials

Yojana Jeevane has more than four years of experience in market intelligence and business research. She has experience in the healthcare domain with respect to medical devices, the life sciences market, and in the chemical domain. She has frequently delivered research services that contain strategic recommendations and top business strategies to help market players make strategic decision. She holds an MBA in Marketing.